Chinese Adults With Kidney Disease

Recruiting now · Phase 2

Conditions studied: Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G), IC-MPGN

In brief

This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).

Key facts

Study ID

NCT07522099

Run by

ADARx Pharmaceuticals, Inc.

People needed

30

Starts

2026-05-21

Expected to finish

2029-01-21

Last updated by the study team

2026-07-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Mean eGFR greater than or equal to 30 mL/min/1.73m2
• Clinical evidence of active kidney disease
• Treated with supportive care including an ACE inhibitor or ARB if applicable
• Willing to receive required vaccinations
• Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy

You may not qualify if…

• Previous kidney transplant or major solid organ transplant
• Required renal replacement therapy for more than 72 hours
• Rapidly progressive glomerular nephritis or acute kidney injury
• History of recurrent invasive infection
• Current or previous use of C5 or CFB inhibitors (such as eculizumab, ravulizumab or iptacopan)
• Active TB, HIV or other systemic infection
• Abnormal liver function

Where it is running

• ADARx Clinical Site — Shanghai, China (enrolling)
• ADARx Clinical Site — Guiyang, Guizhou, China (enrolling)
• ADARx Clinical Site — Shenzhen, Guangdong, China (enrolling)
• ADARx Clinical Site — Baotou, Inner Mongolia, China (enrolling)
• ADARx Clinical Site — Wuxi, Jiangsu, China (enrolling)
• ADARx Clinical Site — Yantai, Shandong, China (enrolling)
• ADARx Clinical Site — Beijing, China (enrolling)
• ADARx Clinical Site — Shandong, China (enrolling)
• ADARx Clinical Site — Zhengzhou, Henan, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.